Immunological mechanism and correspondent antigen of anti PD-1/PD-L1 antibody Related lung adverse events

Immunological mechanism and correspondent antigen of anti PD-1/PD-L1 antibody Related lung adverse events - IR-Lung study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000035125

Enrollment

Registered

2018-12-03

Start date

2018-12-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small-cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients who had anti-PD-1/PD-L1 antibody treatment in patients with advanced non-small cell lung cancer 2. Patients who appeared new pulmonary abnormal shadows that did not appear in chest CT before treatment during anti-PD-1/PD-L1 antibody treatment 3. Patient who gets written consent form

Exclusion criteria

Exclusion criteria: 1. Patients who have judged that their participation in this study is inappropriate

Design outcomes

Primary

Measure	Time frame
To elucidate the responsible T cell fraction of onset pulmonary adverse events by anti PD-1 / PD-L1 antibody therapy	—

Countries

Japan

Contacts

Public ContactOu Yamaguchi

Saitama Medical University International Medical Center Respiratory medicine

ouyamagu@saitama-med.ac.jp042-984-4111

Outcome results